单克隆免疫球蛋白血症患者M蛋白质量浓度检测的临床意义

来源期刊：广州医药 | 669-674 发布时间：2025-06-17 收稿时间：2025/11/13 18:53:48 阅读量：35

作者：: 钟煜民,

黄冬连,

谢祖刚,

郭耿耿,

关键词：: 单克隆免疫球蛋白血症 M蛋白血液系统恶性肿瘤临床意义影响因素肾脏疾病; monoclonal gammopathy M protein hematological malignancies clinical significance influencing factors kidney disease

DOI：: 10.20223/j.cnki.1000-8535.2025.05.014

收稿时间：: 2024-04-29
修订日期：
接收日期：
引用总数：: 0

目的探讨单克隆免疫球蛋白血症患者M蛋白质量浓度检测的临床意义。方法选取2018年6月—2023年6月龙岩人民医院收治的88例单克隆免疫球蛋白血症患者为研究对象,其中意义未明单克隆免疫球蛋白血症（MGUS）21例,具有肾脏意义单克隆免疫球蛋白血症（MGRS）50例,血液系统恶性肿瘤17例。对比其M蛋白质量浓度及临床实验室相关指标表达水平,采用Spearman相关分析法分析临床实验室相关指标的与M蛋白的相关性,对所有患者进行半年随访,以预后情况作为因变量,纳入Logistics回归模型分析M蛋白质量浓度对单克隆免疫球蛋白血症预后的预测价值。结果不同病种M蛋白水平分别为（2.42±0.55）（2.57±0.64）（4.36±0.64）g/L、24 h尿蛋白分别为（1.45±0.16）（2.98±0.68）（2.43±0.44）g/24 h、血清白蛋白质量浓度分别为（31.01±3.06）（35.03±5.04）（39.05±7.08）g/L、总胆固醇水平分别为（3.42±1.25）（3.87±0.64）、（4.16±0.64）mmol/L、血肌酐水平分别为（114.35±23.23）（81.18±12.12）（146.36±21.12）μmol/L、血红蛋白质量浓度分别为（148.12±15.26）（141.69±12.15）（133.34±15.31）g/L,组间对比差异均有统计学意义（F分别为23.890,19.700,12.044,25.767,36.572,10.267,P<0.05）。MGUS患者24h尿蛋白与M蛋白有相关性（r=-0.384,P=0.033）,24 h尿蛋白、血清白蛋白、总胆固醇、血肌酐与MGRS患者M蛋白有相关性（r=-0.586,P=0.006;r=0.431,P=0.018;r=-0.457,P=0.020;r=0.523,P=0.009）,血清白蛋白、总胆固醇、血红蛋白与血液系统恶性肿瘤患者M蛋白有相关性（r=0.374,P=0.029;r=-0.617,P=0.001;r=-0.414,P=0.024）;年龄、M蛋白为单克隆免疫球蛋白血症患者预后的影响因素（P<0.05）。结论不同单克隆免疫球蛋白血症患者M蛋白水平存在差异,其中血液系统恶性肿瘤患者的M蛋白水平最高,且M蛋白为单克隆免疫球蛋白血症预后的独立影响因素。

Objective To explore the clinical significance of detecting M protein concentration in patients with monoclonal gammopathy．Methods From June 2018 to June 2023,88 patients with monoclonal gammopathy admitted to the hospital were selected as the study subjects．Among them,21 cases of monoclonal gammopathy with undetermined significance（MGUS）,50 cases of monoclonal gammopathy with renal significance（MGRS）,and 17 cases of hematological malignancies were selected． Concentration of M protein and the expression levels of clinical laboratory related indicators were compared,Spearman correlation analysis was used to analyze the correlation between clinical laboratory related indicators and M protein．All patients were followed up for six months,with prognosis as the dependent variable,included in the logistic regression model to analyze the predictive value of M protein concentration on the prognosis of monoclonal gammopathy．Results There were significant differences in the expression levels of M protein（[2.42±0.55],[2.57±0.64],[4.36±0.64]）g/L,24-hour urine protein（[1.45±0.16],[2.98±0.68],[2.43±0.44]）g/24 h,serum albumin（[31.01±3.06],[35.03±5.04],[39.05±7.08]）g/L,total cholesterol（[3.42±1.25],[3.87±0.64],[4.16±0.64]）mmol/L,blood creatinine（[114.35±23.23],[81.18±12.12],[146.36±21.12]）μmol/L,and hemoglobin（[148.12±15.26],[141.69±12.15],[133.34±15.31]）g/L among different diseases（F=23.890,19.700,12.044,25.767,36.572,10.267;P<0.05）．There was a significant correlation between 24 h urinary protein and M protein in MGUS patients（r=-0.384,P=0.033）．Urinary protein,serum albumin,serum cholesterol and blood creatinine were significantly associated with M protein in MGRS patients（r=-0.586,P=0.006;r=0.431,P=0.018;r=-0.457,P=0.020;r=0.523,P=0.009）,Serum albumin,total cholesterol,and hemoglobin were significantly associated with M protein in patients with hematological malignancies（r=0.374,P=0.029;r=- 0.617,P=0.001;r=-0.414,P=0.024;P<0.05）．Age and M protein were independent risk factors for the prognosis of patients with monoclonal gammopathy（P<0.05）．Conclusions There are significant differences in the concentration of M protein among patients with different levels of monoclonal gammopathy,with the highest level observed in patients with hematological malignancies．M protein is an independent prognostic factor for monoclonal gammopathy．

1、林孝怡,卢洁,施新明.95例意义未明的单克隆丙种球蛋白血症实验室特征分析[J].检验医学,2020,35(10):1040-1042.

2、胡楠,王素霞,农琳,等.第565例血尿—蛋白尿—发热—脾大—单克隆免疫球蛋白血症[J].中华医学杂志,2022,102(42):3401-3404.

3、张亦儒,刘丰,田红,等.单克隆免疫球蛋白血症患者M蛋白浓度检测的临床意义[J].肾脏病与透析肾移植杂志,2021,30(2):130-135.

4、游俊丽. 单克隆免疫球蛋白血症伴C3肾小球肾炎、腹壁脂肪淀粉样变性一例[J].中华肾脏病杂志,2020,36(9):714-715.

5、 CáRDENAS M C,GARCíA-SANZ R,PUIG N,et al.Recommendations for the study of monoclonal gammopathies in the clinical laboratory.A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy.Part I:Update on laboratory tests for the study of monoclonal gammopathies[J].Clin Chem Lab Med CCLM,2023,61(12):2115-2130.

6、 DU J,HU Z.Systematic review and meta-analysis of the clinical features of MGRS[J].BMC Nephrol,2024,25(1):22.

7、王露婷,刘贝贝,陆丽娜,等.FLT3与TET2突变的急性髓系白血病伴IgA-κ型单克隆免疫球蛋白血症1例报告[J].海军军医大学学报,2022,43(10):1225-1228.

8、卢珊,董奕君,张艳,等.12例血栓性微血管病变合并单克隆免疫球蛋白血症患者临床病理及预后分析[J].中华肾脏病杂志,2021,37(1):43-46.

9、张萍,汪伟,姚琪,等.单克隆免疫球蛋白血症患者肾脏损害的临床病理特征[J].中华病理学杂志,2020,49(4):348-350.

10、李超,文煜冰,李航,等.血游离轻链在有肾脏意义的单克隆免疫球蛋白血症中的诊断价值[J].中华医学杂志,2017,97(30):2344-2348.

11、王勉,郭志勇,赖学莉.肾脏意义的单克隆免疫球蛋白血症合并血栓性微血管病1例[J].临床肾脏病杂志,2022,22(9):790-792,封3.

12、魏宇君,李新,申曼,等.肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J].中国全科医学,2021,24(18):2359-2363.

13、王海洋,鲍金凤,袁玖莲,等.慢性粒细胞白血病合并意义未明的单克隆免疫球蛋白血症1例并文献复习[J].徐州医科大学学报,2021,41(1):26-29.

14、 CASTANEDA-AVILA M A,ULBRICHT C M,EPSTEIN M M.Risk factors for monoclonal gammopathy of undetermined significance:A systematic review[J].Ann Hematol,2021,100(4):855-863.

15、蒋翔宁,陈俊峰,汪勇.血清游离轻链κ/λ比值联合免疫固定电泳在多发性骨髓瘤患者预后评估中的价值[J].中国实验血液学杂志,2020,28(1):191-195.

16、许燕燕,杨翌翔.骨髓增生异常综合征伴意义未明单克隆免疫球蛋白血症1例[J].国际医药卫生导报,2022,28(20):2941-2943.

17、郭锦洲,赵亮,黄湘华.红细胞增多、双侧肾周积液伴单克隆免疫球蛋白血症[J].肾脏病与透析肾移植杂志,2022,31(1):95-100.

18、栗瑞敏,许玲,王菊美,等.骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症1例诊治分析[J].南昌大学学报(医学版),2021,61(1):102-103,106.

19、中华医学会血液学分会,中国抗癌协会血液肿瘤专业委员会,中国少见浆细胞病协作组.有临床意义的单克隆免疫球蛋白血症的诊断及鉴别诊断中国专家共识(2022年版)[J].中华血液学杂志,2022,43(8):631-635.

20、 SINGH S,MURAD M H,FUMERY M,et al.Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease:A systematic review and network meta-analysis[J].Lancet Gastroenterol Hepatol,2021,6(12):1002-1014.

21、 SAIDHA S,BELL J,HAROLD S,et al.Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis[J].Neurol Sci,2023,44(5):1515-1532.

22、张瑞,王亮,张正昊,等.40岁以上人群中意义未明单克隆免疫球蛋白血症的发病情况分析[J].中国实验血液学杂志,2019,27(2):623-628.

23、庄晶,曲悦,姜鸿.单克隆免疫球蛋白血症合并肾损害患者临床病理特征及预后分析[J].临床肾脏病杂志,2023,23(9):705-711.

24、 GERTZ M A,DISPENZIERI A.Systemic amyloidosisrecognition,prognosis,and therapy:A systematicreview[J].JAMA,2020,324(1):79-89.

25、高歌,张鑫越,董奕君,等.单纯膜性肾病与膜性肾病合并意义未明单克隆免疫球蛋白血症的差异性探讨[J].天津医药,2023,51(8):878-882.